10x Genomics, Inc. (TXG) Stock Price & How to Invest

10x Genomics, Inc. (Nasdaq: TXG) builds instruments, reagents, and software for single-cell and spatial biology, the tools scientists use to read gene activity one cell at a time and map it across intact tissue. Its core franchises are Chromium (single-cell analysis), the Visium and Xenium spatial platforms, and the newly launched Atera in situ system (list price around $495,000, shipping in the second half of 2026). Revenue skews toward recurring consumables sold to academic labs, pharma and biotech research groups, and core genomics facilities, with instrument placements driving the razor-and-blade model over time.

The investment picture is a category leader growing slowly through a rough patch. Trailing-twelve-month revenue is roughly $639M with the company still running a modest net loss, though gross margin has improved to about 70% and the balance sheet carries roughly $540M of cash and no debt. Full-year 2026 guidance of $600M to $625M implies only 0% to 4% growth after stripping out one-time patent-settlement revenue, reflecting a deep freeze in academic and biopharma capital-equipment budgets (instrument sales fell about 24% year over year in Q1). The stock (market cap roughly $5B, price-to-sales near 7x) is priced on the expectation that consumables growth and new platforms like Atera eventually reaccelerate the top line.

The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis, so the valuation (price-to-sales near 7x) leans heavily on a growth reacceleration that may not arrive on schedule. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.

13 analysts publish price targets on TXG, averaging $41.54 against a $47.27 price as of August 2026, or -12.1%. The published targets run from $25.00 to $50.00, a moderate spread, and the ratings split 6 buy, 10 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full TXG forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on 10x Genomics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Consumables-led recurring revenue. Even with instrument sales frozen, consumables grew about 13% year over year in Q1 2026 as the large installed base of Chromium and spatial instruments keeps ordering reagents. The most optimistic published target, $50.00, assumes this works close to its best case.

The case against. The biggest overhang is demand: U.S. The most pessimistic target, $25.00, is roughly what TXG is worth if this bites instead.

Read the full bull and bear case on TXG, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see 10x Genomics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$639M
• Q1 2026 revenue: ~$150.8M
• 2026 revenue guidance: ~$600M-$625M
• Gross margin: ~70%
• Cash & securities (no debt): ~$540M
• Market cap: ~$5B

10x Genomics trades at roughly 7x sales while revenue is essentially flat and the company still runs a small net loss, so the market is paying for future growth rather than current profits. The debt-free balance sheet with about $540M of cash gives it room to fund new launches. The key swing factor is whether academic and biopharma spending thaws enough to restart instrument placements.

If you want TXG exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to TXG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get TXG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ARKG), which spreads the position across many companies. Or build it into a focused thematic portfolio, so TXG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where TXG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

10x Genomics is a category leader in single-cell and spatial genomics trading on future growth while near-term results stay flat under an academic-funding freeze.

Whether TXG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TXG a buy or a sell?, and where the stock could go from here in the TXG stock forecast.

For income investors, whether TXG pays a dividend and how the payout looks is covered in does TXG pay a dividend? And to weigh TXG against a peer, read the full side-by-side comparisons: TXG vs BRKR and TXG vs ILMN.